Brian Fenton, Photys CEO

Go­ing be­yond pro­tein degra­da­tion, a new Broad start­up kicks in­to gear to fix pro­tein func­tion­al­i­ty

There’s a pletho­ra of pro­tein degra­da­tion biotechs, and a small­er hand­ful of pro­tein sta­bi­liza­tion play­ers, but Lizzie Ngo was search­ing for some­thing more.

The prin­ci­pal at Long­wood Fund, the in­vest­ment firm be­hind the likes of Bi­cy­cle Ther­a­peu­tics, want­ed to know, “What else could we do be­yond just tar­get­ed pro­tein degra­da­tion?” she told End­points News.

While map­ping out the space, she and a col­league came across a 2020 pa­per from Amit Choud­hary’s lab at MIT and Har­vard’s Broad In­sti­tute. As so many biotechs’ ori­gin sto­ries be­gin, the pa­per led to a new start­up with am­bi­tions go­ing be­yond pro­tein degra­da­tion and sta­bi­liza­tion and in­to ac­ti­va­tion, in­ac­ti­va­tion and traf­fick­ing of pro­teins.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.